MVI Vaccine to Be Used in Clinical Trial of a New Combination Approach to Immunotherapy Funded by the Prostate Cancer Foundation and the Movember Foundation

Trial Pairs MVI-816 with a PD-1 Pathway Inhibitor to Treat Metastatic Prostate Cancer Prostate Cancer Foundation/Movember Foundation Award Goes to the University of Wisconsin to Conduct the Clinical Trial August 27, 2014 Madison Vaccines Incorporated (MVI), a clinical stage biopharmaceutical company, today said its lead product candidate MVI-816 (pTVG-HP) will be used in a clinical trial testing a two-pronged immunotherapy …